Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CT-868 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants in the placebo arm received volume- and regimen-matched placebo. |
| CT-868 1.75 mg | EXPERIMENTAL | Participants in the CT-868 1.75 mg arm received 1.0 mg/day for 2 weeks followed by 1.75 mg/day for the remaining treatment period. |
| CT-868 4.0 mg | EXPERIMENTAL | Participants in the CT-868 4.0 mg arm escalated through 1.0 mg/day for 2 weeks, 1.75 mg/day for 2 weeks, 2.5 mg/day for 4 weeks, 3.25 mg/day for 4 weeks, to 4.0 mg/day for the remaining 14 weeks. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Participants self-injected once-daily subcutaneous volume- and regimen-matched placebo for 26 weeks. |
| CT-868 | DRUG | Participants self-injected once-daily subcutaneous CT-868 for 26 weeks according to the randomized dose and regimen. |
Inclusion Criteria: * Males or Females with T2DM * BMI of ≥27 kg/m2, inclusive * 18-75 years old, inclusive * Stable body weight for 3 months Exclusion Criteria: * Significant medical history * Uncontrolled diabetes * History of malignancy
Top 20 of 32 competitors
CT-868 is an investigational small molecule being developed for obesity. It was studied in overweight and obese participants with type 2 diabetes mellitus. The drug is in Phase 2 clinical development and is not yet approved by regulatory authorities.
CT-868 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in metabolic conditions such as obesity.
CT-868 is in Phase 2 clinical development. A Phase 2 trial has been completed, and the drug remains investigational. It has not been approved by the FDA or any other regulatory agency for the treatment of obesity.
CT-868 has one completed clinical trial, identified as NCT05110846. This Phase 2 study enrolled 103 participants and evaluated the drug in overweight and obese individuals with type 2 diabetes mellitus. The trial was randomized, double-blind, and placebo-controlled.
CT-868 is a distinct investigational small molecule developed by Roche. No alternative names for CT-868 have been identified in the available clinical trial information. It is being studied specifically for its potential role in treating obesity.